AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Now approved for both acute and chronic HCV in adults and children aged 3 and above
This strategic expansion marks a significant step in the company's global growth strategy
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
EBITDA before special items decreases to €4.08 billion (7.4%)
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Subscribe To Our Newsletter & Stay Updated